SERIES B COMMON STOCK PURCHASE WARRANT CORMEDIX INC.CorMedix Inc. • May 3rd, 2017 • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date and on or prior to the close of business on the day that is the fifth (5th) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from CorMedix Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
UNDERWRITER’S PURCHASE WARRANT CORMEDIX INC.CorMedix Inc. • May 3rd, 2017 • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date and on or prior to the close of business on the day that is April 28, 2022 (the “Termination Date”) but not thereafter, to subscribe for and purchase from CorMedix Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). The warrant is issued pursuant to that certain Underwriting Agreeemnt, dated April 28, 2017, between the Company and H.C. Wainwright & Co., LLC.
16,190,697 Shares of Common Stock ($0.001 Par Value) and Warrants to Purchase up to 24,286,044 Shares of Common Stock CorMedix Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • May 3rd, 2017 • CorMedix Inc. • Pharmaceutical preparations • New York
CorMedix Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom you are acting as the representative (the “Representative”) (i) an aggregate of 16,190,697 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value (the “Common Stock”) and (ii) warrants of the Company to purchase an aggregate of 24,286,044 shares of Common Stock (the “Firm Warrants” and, together with the Firm Shares, the “Firm Securities”). The respective amounts of the Firm Securities to be so purchased by the several Underwriters are set forth opposite their names in Schedule I hereto. The Company also proposes to sell at the Underwriters’ option (i) an aggregate of up to 2,428,604 additional shares of the Company’s Common Stock (the “Option Shares” and, together with the Firm Shares, the “Shares”) and/or (ii) warrants of the Company to purchase up to an additional 3,642,906 shares of Common Stock (the “Option
